Anesiva Announces Filing of New Drug Application for Zingo™ to Reduce Pain Associated with Needle Insertion Procedures in Children
Anesiva, Inc. announced that the company has filed a New Drug Application (NDA) with the FDA for marketing clearance of Zingo™ to treat the pain associated with venous access procedures in children. As part of the company's continued development of Zingo, Anesiva expects to begin a follow-on clinical trial in adults in early 2007. As previously announced, Anesiva has obtained commitments to purchase approximately $45 million of its common stock, which it anticipates closing on November 28, 2006.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment